Raymond James & Associates Sarepta Therapeutics, Inc. Call Options Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 25, 2023	BUY	$106.4 - $157.19 $106,400 - $157,190	1,000 New	1,000 $114,000
Q4 2022 Feb 08, 2023	BUY	$100.86 - $132.13 $937,998 - $1.23 Million	9,300 New	9,300 $1.21 Million
Q1 2022 May 11, 2022	SELL	$63.15 - $90.42 $663,075 - $949,410	-10,500 Reduced 50.0%	10,500 $76,000
Q4 2021 Feb 08, 2022	SELL	$77.28 - $99.42 $2.67 Million - $3.43 Million	-34,500 Reduced 62.16%	21,000 $261,000
Q3 2021 Nov 02, 2021	BUY	$65.97 - $92.48 $2.44 Million - $3.42 Million	37,000 Added 200.0%	55,500 $697,000
Q1 2021 May 14, 2021	SELL	$72.25 - $168.95 $1.91 Million - $4.46 Million	-26,400 Reduced 58.8%	18,500 $181,000
Q4 2020 Feb 12, 2021	SELL	$125.56 - $178.74 $12,556 - $17,874	-100 Reduced 0.22%	44,900 $2.56 Million
Q3 2020 Nov 04, 2020	SELL	$127.12 - $172.34 $25,424 - $34,468	-200 Reduced 0.44%	45,000 $900,000
Q1 2020 Apr 21, 2020	SELL	$82.38 - $131.64 $82,380 - $131,640	-1,000 Reduced 2.16%	45,200 $443,000
Q4 2019 Feb 12, 2020	BUY	$76.53 - $135.58 $153,060 - $271,160	2,000 Added 4.52%	46,200 $1.13 Million
Q3 2019 Nov 07, 2019	SELL	$72.81 - $156.91 $203,868 - $439,348	-2,800 Reduced 5.96%	44,200 $155,000
Q2 2019 Aug 06, 2019	BUY	$112.21 - $151.95 $5.27 Million - $7.14 Million	47,000 New	47,000 $1.96 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.